



DOI: 10.1515/rrlm-2017-0026

## Pitfalls in hemostasis exploration, a case report of a girl with Henoch-Schönlein type vasculitis

Smaranda Arghirescu<sup>1</sup>, Eugen Boia<sup>1</sup>, Emilia Ursu<sup>2</sup>, Delia Savescu<sup>2</sup>, Madalina Boc<sup>2</sup>, Cristian Jinca<sup>1</sup>, Margit Serban<sup>2\*</sup>

1. University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania

2. Clinical Emergency Children's Hospital "Louis Turcanu" Timisoara, Romania

### Abstract

*The adequate performance and correct interpretation of assays for coagulation factor inhibitors play a critical role for the hemostasis laboratory. Both, false positive and false negative inhibitor assays may be reported, leading to erroneous patient's management. Therefore, we decided to present a case with a spurious image of an exceptionally rare acquired combined haemophilia A, B and C, with severe factor (F) VIII, IX and XI deficiency, associated with high titre anti - F VIII, IX and XI inhibitors in a 4 years old girl with Henoch-Schönlein type vasculitis. Finally, performing, beside coagulometric methods also antigenic ELISA assays, we had to invalidate the diagnosis. The performance of antiphospholipid antibodies clarified the diagnosis, finally concluding as definite diagnosis Transient Lupus Anticoagulant Syndrome, with decisive impact on therapy and follow-up.*

**Keywords:** acquired haemophilia, lupus anticoagulant, Henoch-Schönlein vasculitis, children, antiphospholipid antibody syndrome

Received: 04<sup>th</sup> May 2017; Accepted: 10<sup>th</sup> July 2017; Published: 10<sup>th</sup> July 2017

### Introduction

Acquired haemophilia (AH) is a rare (0.045/ million/ year in children) bleeding disorder with high morbidity and mortality, due to the development of autoantibodies against coagulation factors, namely anti-FVIII, extremely seldom anti-F IX and exceptionally rare combined anti-F VIII and F IX; to our knowledge, a tripple association (anti-F VIII, F IX and F XI) was not described until now. (1, 2)

Lupus anticoagulants (LA) belong to the heterogeneous group of antibodies directed against

negatively charged phospholipids, with a prevalence of approximately 5% in adults and more than 20% in children and adolescents. (3) LA is a double misnomer: it is only seldom associated to systemic lupus erythematosus and almost never causes bleeding disorders. (4,5)

An associated AH with LA is also uncommonly reported. (6) Their coexistence is a „thorny” issue. (7)

Although a great deal of information is available in the literature on the frequency, clinical and laboratory findings, significance of LA in

\*Corresponding author: Margit Serban, Clinical Emergency Children's Hospital "Louis Turcanu" Timisoara, Romania, e-mail: mserban@spitalcopiitm.ro

adults, little is known about acquired inhibitors in children. (8)

Therefore, in the following case report we will present the complexity of hemostatic alterations leading to an initial misdiagnosis in a paediatric patient with LA, in order to avoid extensive expensive workup and / or expensive, unnecessary treatments .

## Case report

A previously healthy 4 year old girl, without significant personal or familial pathologic background, presented for 6-7 days prior to the admission in our clinic, high fever, sore throat and non-productive cough. Her clinical evolution was initially favorable under

ambulatory symptomatic treatment. However, 2 days before presentation in our department, she developed symmetrically, distally distributed petechiae and hemorrhagic maculo-papulae on the lower and upper extremities, followed by ecchymotic lesions on the shank and thorax, accompanied by arthralgia. No evident arthritis, edema, hepatosplenomegaly were observed. The cardio-pulmonary and neurological examination were within physiological parameters. The initial laboratory studies revealed a normal red blood cells count ( $4.86 \times 10^6/\text{mm}^3$ ), white blood cells count ( $7.69 \times 10^3/\text{mm}^3$ ) and platelets count ( $348 \times 10^3/\text{mm}^3$ ); liver and renal function tests were normal (ASAT-26IU/L; ALAT-9IU/L; creatinine- $26 \mu\text{mol/l}$ ), furthermore the urine analysis was within normal ranges. Coagulation

**Table I. Hemostatic alterations, coagulation factors activity and plasmatic levels of inhibitors titers**

|                                                               | Normal ranges | Day 1-3    | Day 14       | Day 44      | Day 88 |
|---------------------------------------------------------------|---------------|------------|--------------|-------------|--------|
| <b>APTT(s)</b>                                                | 25-36         | 113.2      | <b>97</b>    | <b>51.5</b> | 28.2   |
| <b>PT(s)</b>                                                  | 9-14          | 15.9       | 12.3         | 11.4        | 11.3   |
| <b>Prothrombin index (%)</b>                                  | 75-140        | <b>65</b>  | 93           | 105         | 106    |
| <b>TT(s)</b>                                                  | 11-19         | 18.1       | 16.1         | 19.2        | 14.7   |
| <b>Prothrombin consumption test(s)</b>                        | >40           | >120       | 90           | 43          | -      |
| <b>FVIII(%)</b>                                               | 70-150        | <b>0.1</b> | <b>13.5</b>  | 124.3       | 170.3  |
| <b>FIX(%)</b>                                                 | 60-130        | <b>0</b>   | <b>8.5</b>   | 90.4        | 93     |
| <b>FXI(%)</b>                                                 | 65-150        | <b>0</b>   | <b>7.3</b>   | 83.9        | 112.2  |
| <b>FXII(%)</b>                                                | 70-150        | 70         | 65           | 88          | -      |
| <b>Antigen vWF (%)</b>                                        | 50-150        | 96.6       | 110.5        | 171         | 119.6  |
| <b>Activity vWF(%)</b>                                        | 50-150        | 87.9       | 101.2        | 160         | 119.9  |
| <b>FI(mg/dl)</b>                                              | 200-400       | 279        | 298          | 332         |        |
| <b>Inhibitors anti FVIII (BU/ml)</b>                          | <0.6          | <b>3</b>   | <b>28.85</b> | 0           | 0      |
| <b>Inhibitors anti FIX (BU/ml)</b>                            | <0.6          | <b>3.2</b> | <b>36.9</b>  | 0           | 0      |
| <b>Inhibitors anti FXI (BU/ml)</b>                            | <0.6          | -          | <b>5</b>     | 0           | 0      |
| <b>Zymotest anti-Faktor VIII (IgG) ELISA (Hyphen) (AU/ml)</b> | <12           | -          | 5.9          | 5.6         | -      |
| <b>Zymotest anti-Faktor VIII (IgA) ELISA (Hyphen) (AU/ml)</b> | <10           | -          | 0.9          | 1.4         | -      |
| <b>In-house anti-Faktor IX (IgG) ELISA (Hyphen) (AU/ml)</b>   | negative      | -          | negative     | negative    | -      |

APTT - Activated Partial Thromboplastin Time (s), PT - Prothrombin Time (s), PI - Prothrombin Index (%), FVIII - factor eight; FIX - factor nine; FXI - factor eleven; FXII-factor twelve; vWF- vonWillebrand factor; FI- Fibrinogen, FVIII - factor eight; FIX - factor nine; FXI - factor eleven; BU - Bethesda Unit.

exploration performed using ACL TOP 300 coagulation analyzer through optical method, using silico-activated reagent revealed a persistent and significantly prolonged activated partial thromboplastine time (aPTT), with normal prothrombin consumption (PC), thrombin (TT) and prothrombin time (PT) and index (PI), vWF (von Willebrand faktor) antigen and activity, FXII (Table I); thromboelastography (TEG) was also normal (Table II). Plasma mixing with normal standard control plasma failed to correct the aPTT, suggesting the presence of an inhibitor. Indeed, the inhibitor testing showed, in an astonishing manner, the presence of high titer inhibitors anti-FVIII, IX and XI, and a significantly depressed activity for the correspondent factors (Table I). Searching for the ethiological background, we investigated lupic cells, complement C3/C4, rheumatoid factor, antinuclear antibodies, antiphospholipid, anti-cardiolipin, anti-beta 2 glicoprotein I (Table III) and antistreptolysin O antibodies, and at the same time serological exploration for hepatitis B, hepatitis C, HIV, cytomegalovirus,

adenovirus, Epstein-Barr virus (EBV), herpes simplex and toxoplasma, all with negative results; investigations for rotavirus, adenovirus, Salmonella spp, Shigella spp, enteropathogenic Escherichia coli revealed also normal results.

From the investigated anti-phospholipid antibodies, only LA, explored by mixing test with normal platelet poor standard plasma added to patient's plasma and by DRVVT (diluted Russell's viper venom time) was repeatedly present.

Because of the stable condition of the child on admission and the absence of complications, as well as the progressive resolution in 7 days of the hemorrhagic symptoms we adopted a „watch and wait” strategy. The titre of factor VIII, IX and XI increased progressively to normal values, whereas the level of inhibitors declined simultaneously; after 44 days, the asymptomatic patient, was with almost normal coagulometric values; a slight increase of aPTT, as well LA was still present. After 88 days LA investigations revealed negative values. (Table I, II)

In doubt of the diagnosis regarding acquired combined severe haemophilia A, B and C, and because of the lack of correlation between the severity of biologic hemostatic alterations and the mildness of clinical expression, and above all, because of the constantly discordant high values of the prothrombin consumption test and normal TEG parameters (Table II) we extended the coagulometric exploration of the inhibitors anti-FVIII and IX with antigenic ELISA tests.

**Table II. Thromboelastography (TEG) parameters**

|                      | <b>R(s)</b> | <b>K(min)</b> | <b>MA(mm)</b> |
|----------------------|-------------|---------------|---------------|
| <b>Normal ranges</b> | 2-8         | 1-3           | 51-69         |
| <b>Day 1-3</b>       | 7           | 2.1           | 62.7          |
| <b>Day 14</b>        | 6.8         | 1.8           | 51.4          |
| <b>Day 44</b>        | 5           | 1.1           | 67.5          |

R - reaction time (s), K- kinetics (s), MA - maximum amplitude (mm)

**Table III. Antiphospholipid antibodies**

|                                                | <b>Normal ranges</b> | <b>Day 1-3</b> | <b>Day 14</b> | <b>Day 44</b> | <b>Day 88</b> |
|------------------------------------------------|----------------------|----------------|---------------|---------------|---------------|
| <b>Lupic anticoagulant(s)</b>                  | 30.4-45.3            | -              | <b>88.6</b>   | <b>52.4</b>   | 41.3          |
| <b>Anti-phospholipid antibodies IgM (U/ml)</b> | <10                  | -              | 0.8           | 1.2           | -             |
| <b>Anti-phospholipid antibodies IgG</b>        | <10                  | -              | 1.3           | 2.1           | -             |
| <b>Anti-cardiolipin antibodies IgM (U/ml)</b>  | <7                   | -              | 1.6           | 1.3           | -             |
| <b>anti-cardiolipin antibodies IgG (U/ml)</b>  | <10                  | -              | 4             | 2.1           | -             |
| <b>anti-beta 2 glicoprotein I IgM (U/ml)</b>   | <5                   | -              | 1.73          | 2.55          | -             |
| <b>anti-beta 2 glicoprotein I IgG (U/ml)</b>   | <5                   | -              | 0.98          | 1.22          | -             |

Zymotest Anti-FVIII (IgG and IgA) ELISA (Hyphen) and Anti-F IX (IgG and IgA) ELISA (Hyphen) were performed in the Haemostasis Laboratory of Medizinische Hochschule Hannover (Germany), remaining negative (Table I). Consequently, lacking the evidence of the presence of anti - F VIII and anti - F IX inhibitors, lupus anticoagulant syndrome was established. After 88 days the patient's clinical examination revealed a healthy, cooperative girl without bleeding signs or complains. The patient will remain in clinical and biological follow-up.

## Discussion

LA together with anti-cardiolipin (aCL) and anti - beta - 2 glicoprotein I (anti-beta-2 GPI) belongs to the group of antiphospholipid antibodies responsible for the Antiphospholipid Antibody Syndrome (APS). But its isolated occurrence (type IIb in the classification according to the Sydney consensus of APS), even in a persistent form (more than 12 weeks), at least in the paediatric population, can radically change the clinical image turning it from the largely recognised and accepted thrombotic risk/manifestation to a clinical bleeding expression (LA hypoprothrombinemia syndrome-LAHS, sometimes associated with mild thrombocytopenia or thrombocytopenia). In the majority of paediatric cases, in contrast to major biological alterations, the patients remain oligo- or asymptomatic. (9-12)

Characteristic for our patient was the significant involvement of coagulations factors alterations (F VIII, F IX, F XI) and the presence of correspondent inhibitors. The coexistence of LA and AH is exceedingly rare. (6,13,14) In many cases they remain a subject of debate: are they present concomitently in reality or are they a false image generated by LA ? It can really be a „thorny issue” to answer this question. (4,7,15) In our case, the ELISA antigenic tests performed

for anti F VIII and IX inhibitors remained negative, which undoubtedly pleaded for a rare type of transient LA syndrome, invalidating the diagnosis of AH-A, B and C.

As presented in the literature, there are still many controversies regarding the reliability of LA tests for their correct detection. (15-18) The important heterogeneity of antibodies, the different types of thromboplastine and other reagents used, the variate modality of measurements (coagulometric or chromogenic), addition of phospholipids also, impose a better standardised diagnostic strategy.

Most physicians agree that LA in children is a benign condition, often with a transient course, lacking significant clinical issues. As presented in our case, the dramatic biological hemostatic alterations may be asymptomatic or with a modest expression, allowing the avoidance of some therapeutical modalities: aggressive, expensive, connected with a high burden of adverse reactions (steroids, immunosuppressive drugs like rituximab, mycophenolate mofetil). (19,20,21) The most benign outcome characterises the postviral or post-medications forms of LA (vaccines, chlorpromazine, amoxicillin, hydralazine). LA associated with autoimmune diseases, malignancies, lymphoproliferative disorders deserve increased attention in long term monitoring, due to their outcome.

In our patient, a LA post Schoenlein Henoch vasculitis, as in other cases reported in literature, the short-term outcome was favorable. (22,23) However, taking into consideration the immunological nature of the disease a long term follow-up, would be advisable.

## Conclusion

Mis -, over - and underdiagnosis of LA and AH are frequent, due to the many interfering factors related to the heterogeneity of antibodies and diversity of clinical images, but also to

the diagnosis modalities (type of reagents and performed assays); however these pitfalls should be avoided due to the high burden of expensive workup and treatment.

### Learning points

- LA is a benign condition in paediatric patients
- It can be challenging, confused with acquired, sometimes severe, multiple type associated haemophilia
- The most frequent modality of evolution is a transient LA with spontaneous resolution
- To minimize extensive and expensive blood workup, a screening for LA is advisable in the evaluation of children with prolonged aPTT, but with negative history of bleeding problems
- A prompt diagnosis and a clinically oriented therapeutical behavior will allow the avoidance of an aggressive and expensive treatment.

### Potential conflict of interest

None declared.

### Acknowledgment

The authors are thankful to Prof. Dr. Andreas Tiede (Med Hoch Hannover-Germany) for his kind and generous support in the antigenic exploration of potential inhibitors.

### References

1. Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. *Pediatr Blood Cancer*. 2010 Oct; 55(4):606-11.
2. Jan Bain M, Leissinger C, Kruse-Jarres R. Acquired hemophilia A: emerging treatment options. *J Blood Med*. 2015 May; 6: 143–150.
3. C.Kallanagowdar, A.Chauhan, M.V.Puertolas, R.Warrier. Prevalence and Resolution of Lupus Anticoagulant in Children. *Ochsner Journal* 2016; 16:172-175.
4. D.Williams, Duncan C. MacIvor. Patient Is Clotting: What Do You Mean, the aPTT is prolonged. *Medscape*, february 21, 2013.
5. Chaturvedi S and McCrae K. The antiphospholipid syndrome: still an enigma. *Hematology Am Soc Hematol Educ Program*. 2015 Dec; 53–60.
6. Gupta D, Chatterjee T, Sharma A, Ganguli P, Das S, Sharma S. Rare case of acquired haemophilia and lupus anticoagulant. *Indian J Hematol Blood Transfus*. 2014 Sep; 30(3): 197–200.
7. P.R.J.Ames, D.Montero, J.Archer. Co-existent Acquired Haemophilia and Lupus Anticoagulant. A Thorny Issue. *Indian J Hematol Blood Transfus*. 2016 Jun; 32(Suppl 1): 248.
8. Singh AK, Rao KP, Kizer J, Lazarchick J. Lupus anticoagulants in children. *Ann Clin Lab Sci*. 1988 Sep-Oct; 18(5):384-7
9. Sreedharanunni S, Ahluwalia J, Kumar N, Bose SK, Dhawan R, Malhotra P. Lupus anticoagulant-hypoprothrombinemia syndrome: a rare cause of intracranial bleeding. *Blood Coagul Fibrinolysis*. 2016 Dec; 10:1097.
10. Sarker T, Roy S, Hollon W, Rajpurkar M. Lupus anticoagulant acquired hypoprothrombinemia syndrome in childhood: two distinct patterns and review of the literature. *Haemophilia*. 2015 Nov; 21(6):754-60.
11. Knobe K, Tedgård U, Ek T, Sandström PE, Hillarp A. Lupus anticoagulants in two children-bleeding due to nonphospholipid-dependent antiprothrombin antibodies. *Eur J Pediatr*. 2012 Sep; 171(9):1383-7.
12. Carvalho C, Viveiro C, Maia P, Rezende T. Acquired antiprothrombin antibodies: an unusual cause of bleeding. *BMJ Case Rep*. Published online 2013 Jan; doi: 10.1136/bcr-2012-007948.
13. A.Taher, R.Abiad, I.Uthman. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. *Lupus* 2003; 12(11):854-6.
14. J.D.Dreisbach, L.P.Dreisbach, D.E.Young, P.B.Dreisbach. Acquired factor VIII inhibitor and lupus anticoagulant presenting with prolonged aPTT: a case report. *Grand Rounds* 2010, 10, 19-24.
15. G.W.Moore. Current Controversies in Lupus Anticoagulant Detection. *Antibodies* 2016, 5(4), 22.
16. Jin J, Zehnder JL. Prozone effect in the diagnosis of Lupus Anticoagulant for the Lupus Anticoagulant-Hy-

- poprothrombinemia Syndrome. *Am J Clin Pathol*. 2016 Aug;146(2):262-7.
17. Adcock DM, Favaloro EJ. Pearls and pitfalls in factor inhibitor assays. *Int J Lab Hematol*. 2015 May; 37Suppl 1:52-60.
  18. Doma SA, Hillarp A, Pajić T, Andoljšek D, Černelč P, Preldžnik Zupan I. Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report. *Biochem Med (Zagreb)*. 2016 Jun; 26(2): 279–284.
  19. Fletcher M, Crombet O, Morales-Arias J. Successful treatment of acquired hemophilia A with rituximab and steroids in a 5-year-old girl. *J Pediatr Hematol Oncol*. 2014 Mar;36(2):103-4.
  20. Yang C, Yu Z, Zhang W, Cao L, Su J, Sha P, Bai X, Wang Z, Ruan C. A single-center clinical study of 22 patients with acquired hemophilia. *ZhonghuaXue Ye XueZaZhi*. 2015 Feb;36(2):107-11.
  21. Wermes C, Niekrens C, Sykora KW. Successful long-time treatment with mycophenolate-mofetil in a child with acquired factor VIII inhibitor. *Hamostaseologie*. 2012 Jul; 32 Suppl 1:75-8.
  22. Joly B, d'Oiron R, Desconclois C, Bendelac L, Rafowicz A, Meyzer C, Labrune P, Veyradier A. Mild hemophilia A fortuitously discovered during Henoch-Schonleinpura. *Arch Pediatr*. 2015 Nov;22(11):1167-70.
  23. Gratton B, Osakwe E. Self-limiting recurrent bullous Henoch-Schonleinpura with lupus anticoagulant. *BMJ Case Rep*. Published online 2015 Jan. doi: 10.1136/bcr-2014-205436.